Publications by authors named "Myagmarjav Dashnyam"
Article Synopsis
- Small molecule targeted therapies for metastatic melanoma show promise, but patients often experience relapse and short-lived responses.
- Adoptive cell transfer (ACT) immunotherapy offers durable responses, but resistance occurs when tumors lose the expression of specific antigens.
- Researchers developed a high throughput screening assay to test about 500 small molecules, identifying four compounds that enhance melanoma antigen expression and improve T cell response, potentially leading to better treatments for resistant BRAF mutant melanoma.
Article Synopsis
- Th17 cells play a major role in autoimmune diseases, highlighting the need for targeted therapies to combat these disorders.
- The study found that the anxiolytic drug FGIN-1-27 effectively inhibits the development and harmful effects of Th17 cells in both laboratory and animal models.
- Interestingly, the drug's effect is not related to its known target, translocator protein (TSPO), but instead functions by changing the metabolism of Th17 cells, leading to a response similar to amino acid starvation and changes in fatty acid levels.
Sci Transl Med
February 2020
Article Synopsis
- Solid tumors trigger an immune response, but this response often aids tumor growth instead of fighting it, mainly due to the presence of tumor-associated macrophages (TAMs).
- RP-182 is a synthetic compound that targets the mannose receptor on M2-like macrophages, reprogramming them from supporting tumors to an antitumor M1-like phenotype, which boosts immune activity.
- In various murine cancer models, RP-182 showed success in slowing tumor growth and enhancing survival, especially when used alongside traditional therapies, while also increasing the phagocytosis of cancer cells by the reprogrammed TAMs.
